Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
| ▸ | BCR | P11274 | 3/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7229573 | 0.87 | CCR1 (0.40) | NPFFR1NPFFR2ACACBACACAAAK1 | |
| SCHEMBL7230300 | 0.85 | ACACB (0.40) | NPFFR1NPFFR2ACACBACACAAAK1 | |
| SCHEMBL7229054 | 0.84 | MAPT (0.47) | NPFFR1NPFFR2ACACBACACA | |
| SCHEMBL7238064 | 0.83 | AAK1 (0.41) | CNR1CYP2A6ACACBACACAAAK1 | |
| SCHEMBL7230679 | 0.82 | PPARG (0.37) | NPFFR1NPFFR2AAK1 | |
| SCHEMBL7231006 | 0.81 | AAK1 (0.45) | AAK1ABL1BCR | |
| SCHEMBL7846551 | 0.80 | CNR1 (0.52) | CNR1CYP2A6ACACBACACABRD9 | |
| SCHEMBL7240889 | 0.80 | TRPV1 (0.39) | NPFFR1NPFFR2CYP2A6ABL1FGFR3 | |
| SCHEMBL7846734 | 0.80 | CNR1 (0.39) | CNR1CYP2A6ACACBACACAKMO | |
| SCHEMBL7846731 | 0.80 | CNR1 (0.39) | CNR1CYP2A6ACACBACACAKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521643-B1 | Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-1157022-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000049015-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-24 | — | — | WO | disclosed |